Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs Rewinding RX

Two GLP-1 desks, one scoreboard. We put HealthRX and Rewinding RX head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 326 · Grade C

Rewinding RX

Visit Rewinding RX Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 60 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make Rewinding RX a bad call — it's best for readers who want longevity-framed glp-1 with md-only review and flat any-dose pricing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
40
Supply Reliability
85
78
Transparency
83
23
Access Breadth
91
70
Clinical Oversight
89
84
Track Record
81
84
HealthRXBrief Score 86 · 60Rewinding RX

Price, coverage & the tracker

HealthRXRewinding RX
Brief Score86/100 (B)60/100 (C)
Semaglutide$189/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageNot publicly listedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Rewinding RX: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.